Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Variopeptyl versus Diphereline in girls with idiopathic central precocious puberty
IRCT20250429065526N1Phase 4Completed
- Sponsor
- Varian Pharmed
- Start
- Jul 2023
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of triptorelin in Idiopathic precocious puberty (CPP) (2 arms), sponsored by Varian Pharmed. Primary endpoints: Uterus size by ultrasound, Ovary size by ultrasound and 5 more. Started Jul 2023; status: completed.
02
Drugs
triptorelin
03
Conditions
Idiopathic precocious puberty (CPP)
Beyond the preview
Go deeper on IRCT20250429065526N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20250429065526N1.